Backed by Morningside, Pinteon’s first clinical program targets toxic tau isoform

After five years performing preclinical work with funding from Morningside Ventures, Pinteon has emerged from stealth mode just as its lead program has reached the clinic to treat tauopathy-associated neurodegenerative diseases.

Based on research by Kun Ping Lu at Harvard

Read the full 398 word article

User Sign In